Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data

Executive Summary

Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.

Advertisement

Related Content

Keeping Track Of New Drugs: US FDA Review Queue Adds Spark Gene Therapy, Amgen Migraine Antibody, Bayer Oncologic
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market
Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Alder Readies To Take On Teva, Others In Migraine
Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal
Teva's Next Blockbuster? Its Anti-CGRP Antibody Prepares For Phase III In Difficult-To-Treat Migraines
Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs
Allergan migraine portfolio grows with Merck CGRP antagonists
Teva, Lilly and Amgen join battle for new $8bn migraine prevention market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel